Alnylam Pharmaceuticals Inc. (ALNY) Price Target Cut to $100.00 by Analysts at FBR & Co
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had its price target lowered by FBR & Co from $180.00 to $100.00 in a research report sent to investors on Thursday. FBR & Co currently has an outperform rating on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the company. Credit Suisse Group AG reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Cowen and Company reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Goldman Sachs Group Inc. reduced their target price on Alnylam Pharmaceuticals from $65.00 to $34.00 and set a neutral rating on the stock in a research note on Thursday. Finally, Stifel Nicolaus reduced their target price on Alnylam Pharmaceuticals from $68.00 to $36.00 and set a hold rating on the stock in a research note on Thursday. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $85.75.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 4.930% during trading on Thursday, hitting $34.425. The company had a trading volume of 2,990,331 shares. Alnylam Pharmaceuticals has a 1-year low of $34.18 and a 1-year high of $110.75. The firm’s market capitalization is $2.95 billion. The company’s 50 day moving average is $71.81 and its 200 day moving average is $66.25.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.19. The business had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.85) EPS. Analysts anticipate that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.00% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $128,000. Seven Eight Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $175,000. Bank of Montreal Can acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $193,000. Finally, BlueMountain Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,500 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.